{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:22:24Z","timestamp":1775841744447,"version":"3.50.1"},"reference-count":168,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRCEP"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Therapy with exogenous interferon and human conditions that feature endogenous interferon\nupregulation may be associated with endothelial damage that primarily involves small blood\nvessels. Endothelial injury associated with interferon may display different clinical expression, including\nthrombotic microangiopathy, Raynaud\u2019s phenomenon, vasculopathy of dermatomyositis\nand atrophic papulosis, interferon-associated skin angiopathy, systemic capillary leak syndrome,\ncollapsing glomerulopathy, interstitial lung disease, pulmonary hypertension, and retinopathy. Interferon-\ninduced endothelial damage involves complement-mediated injury, although pathogenic\nmechanisms by which interferon promote abnormal complement activation on endothelial cells\nare not fully understood. Human interferon-\u03b3 (type II interferon) binds to heparan sulfate on the endothelial\nsurface, suggesting that overproduction of interferon-\u03b3 may hinder factor H attachment\nto the same location. Absence of factor H on self surfaces promotes activation of the alternative\npathway of complement and complement-mediated endothelial damage. Type I interferon typically\ninduces the generation of antibodies. Type I interferon upregulation may elicit the formation of\nautoantibodies against factor H. These autoantibodies block factor H binding to endothelial surfaces,\nabolishing the protective effect of factor H on complement-mediated damage. In addition,\ninterferon induces insulin resistance which is associated with reduced heparan sulfate in the extracellular\nmatrix, including the endothelial surface. Decreased amount of heparan sulfate suppresses\nfactor H attachment, promoting activation of the alternative pathway of complement. Complement\nblockade with eculizumab (a monoclonal antibody against C5) improves endothelial damage in patients\nwith thrombotic microangiopathy and other situations associated with interferon upregulation\nand interferon-induced endothelial injury, suggesting that complement-mediated injury is clinically\nrelevant under conditions that feature interferon overproduction.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0127724328322183240922153629","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T16:01:15Z","timestamp":1728403275000},"page":"122-139","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Interferon Causes Endothelial Injury in Humans"],"prefix":"10.2174","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9997-2568","authenticated-orcid":true,"given":"Maria M.","family":"Adeva-Andany","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Hospital General Juan Cardona, c\/ Pardo Baz\u00e1n, s\/n, Ferrol 15406, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Adeva-Contreras","sequence":"additional","affiliation":[{"name":"School\nof Medicine, Santiago de Compostela University, Santiago de Compostela, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Fernandez-Fernandez","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital General Juan Cardona, c\/ Pardo Baz\u00e1n, s\/n, Ferrol 15406, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matilde","family":"Vila-Altesor","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital General Juan Cardona, c\/ Pardo Baz\u00e1n, s\/n, Ferrol 15406, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira","family":"Castro-Quintela","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital General Juan Cardona, c\/ Pardo Baz\u00e1n, s\/n, Ferrol 15406, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Funcasta-Calderon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital General Juan Cardona, c\/ Pardo Baz\u00e1n, s\/n, Ferrol 15406, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1312625","volume":"371","author":"Liu Y.","year":"2014","unstructured":"Liu Y.; Jesus A.A.; Marrero B.; Yang D.; Ramsey S.E.; Sanchez G.A.M.; Tenbrock K.; Wittkowski H.; Jones O.Y.; Kuehn H.S.; Lee C.R.; DiMattia M.A.; Cowen E.W.; Gonzalez B.; Palmer I.; DiGiovanna J.J.; Biancotto A.; Kim H.; Tsai W.L.; Trier A.M.; Huang Y.; Stone D.L.; Hill S.; Kim H.J.; St Hilaire C.; Gurprasad S.; Plass N.; Chapelle D.; Horkayne-Szakaly I.; Foell D.; Barysenka A.; Candotti F.; Holland S.M.; Hughes J.D.; Mehmet H.; Issekutz A.C.; Raffeld M.; McElwee J.; Fontana J.R.; Minniti C.P.; Moir S.; Kastner D.L.; Gadina M.; Steven A.C.; Wingfield P.T.; Brooks S.R.; Rosenzweig S.D.; Fleisher T.A.; Deng Z.; Boehm M.; Paller A.S.; Goldbach-Mansky R.; Activated STING in a vascular and pulmonary syndrome. N Engl J Med  2014,371(6),507-518","journal-title":"N Engl J Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1053\/j.ajkd.2019.07.010","volume":"75","author":"Abid Q.","year":"2020","unstructured":"Abid Q.; Best Rocha A.; Larsen C.P.; Schulert G.; Marsh R.; Yasin S.; Patty-Resk C.; Valentini R.P.; Adams M.; Baracco R.; APOL1-associated collapsing focal segmental glomerulosclerosis in a patient with stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy (SAVI). Am J Kidney Dis  2020,75(2),287-290","journal-title":"Am J Kidney Dis"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1111\/bjd.14073","volume":"173","author":"Bursztejn A.C.","year":"2015","unstructured":"Bursztejn A.C.; Briggs T.A.; del Toro Duany Y.; Anderson B.H.; O\u2019Sullivan J.; Williams S.G.; Bodemer C.; Fraitag S.; Gebhard F.; Leheup B.; Lemelle I.; Oojageer A.; Raffo E.; Schmitt E.; Rice G.I.; Hur S.; Crow Y.J.; Unusual cutaneous features associated with a heterozygous gain-of-function mutation in IFIH1 : Overlap between Aicardi-Gouti\u00e8res and Singleton-Merten syndromes. Br J Dermatol  2015,173(6),1505-1513","journal-title":"Br J Dermatol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jaad.2009.05.002","volume":"61","author":"Prendiville J.S.","year":"2009","unstructured":"Prendiville J.S.; Crow Y.J.; Blue (or purple) toes: Chilblains or chilblain lupus-like lesions are a manifestation of Aicardi\u2013Gouti\u00e8res syndrome and familial chilblain lupus. J Am Acad Dermatol  2009,61(4),727-728","journal-title":"J Am Acad Dermatol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/bloodadvances.2020001515","volume":"4","author":"Jodele S.","year":"2020","unstructured":"Jodele S.; Medvedovic M.; Luebbering N.; Chen J.; Dandoy C.E.; Laskin B.L.; Davies S.M.; Interferon-complement loop in transplant-associated thrombotic microangiopathy. Blood Adv  2020,4(6),1166-1177","journal-title":"Blood Adv"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"eabg0833","DOI":"10.1126\/sciimmunol.abg0833","volume":"6","author":"Yan B.","year":"2021","unstructured":"Yan B.; Freiwald T.; Chauss D.; Wang L.; West E.; Mirabelli C.; Zhang C.J.; Nichols E.M.; Malik N.; Gregory R.; Bantscheff M.; Ghidelli-Disse S.; Kolev M.; Frum T.; Spence J.R.; Sexton J.Z.; Alysandratos K.D.; Kotton D.N.; Pittaluga S.; Bibby J.; Niyonzima N.; Olson M.R.; Kordasti S.; Portilla D.; Wobus C.E.; Laurence A.; Lionakis M.S.; Kemper C.; Afzali B.; Kazemian M.; SARS-CoV-2 drives JAK1\/2-dependent local complement hyperactivation. Sci Immunol  2021,6(58),eabg0833","journal-title":"Sci Immunol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"e29161","DOI":"10.1371\/journal.pone.0029161","volume":"7","author":"Wong D.","year":"2012","unstructured":"Wong D.; Kea B.; Pesich R.; Higgs B.W.; Zhu W.; Brown P.; Yao Y.; Fiorentino D.; Interferon and biologic signatures in dermatomyositis skin: Specificity and heterogeneity across diseases. PLoS One  2012,7(1),e29161","journal-title":"PLoS One"},{"key":"ref=8","first-page":"2054","volume":"89","author":"Sugano S.","year":"1994","unstructured":"Sugano S.; Yanagimoto M.; Suzuki T.; Sato M.; Onmura H.; Aizawa H.; Makino H.; Retinal complications with elevated circulating plasma C5a associated with interferon-alpha therapy for chronic active hepatitis C. Am J Gastroenterol  1994,89(11),2054-2056","journal-title":"Am J Gastroenterol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1034\/j.1600-0404.2000.00013.x","volume":"101","author":"Myhr K.M.","year":"2000","unstructured":"Myhr K.M.; Sadallah S.; Mollnes T.E.; Meri S.; Nyland H.I.; Schifferli J.; Vedeler C.A.; Interferon-\u03b12a effects on complement activation and regulation in MS patients. Acta Neurol Scand  2000,101(1),30-35","journal-title":"Acta Neurol Scand"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0014-5793(01)02592-3","volume":"500","author":"Kaul M.","year":"2001","unstructured":"Kaul M.; Loos M.; Expression of membrane C1q in human monocyte-derived macrophages is developmentally regulated and enhanced by interferon-\u03b3. FEBS Lett  2001,500(1-2),91-98","journal-title":"FEBS Lett"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"108982","DOI":"10.1016\/j.exer.2022.108982","volume":"218","author":"Udsen M.","year":"2022","unstructured":"Udsen M.; Tagmose C.; Garred P.; Nissen M.H.; Faber C.; Complement activation by RPE cells preexposed to TNF\u03b1 and IFN\u03b3. Exp Eye Res  2022,218,108982","journal-title":"Exp Eye Res"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.molimm.2014.08.005","volume":"63","author":"Loeven M.A.","year":"2015","unstructured":"Loeven M.A.; Rops A.L.W.M.M.; Berden J.H.M.; Daha M.R.; Rabelink T.J.; van der Vlag J.; The role of heparan sulfate as determining pathogenic factor in complement factor H-associated diseases. Mol Immunol  2015,63(2),203-208","journal-title":"Mol Immunol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/0014-5793(91)80225-R","volume":"280","author":"Lortat-Jacob H.","year":"1991","unstructured":"Lortat-Jacob H.; Grimaud J.A.; Interferon-\u03b3 binds to heparan sulfate by a cluster of amino acids located in the C-terminal part of the molecule. FEBS Lett  1991,280(1),152-154","journal-title":"FEBS Lett"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1053\/j.ajkd.2015.03.039","volume":"66","author":"Rigothier C.","year":"2015","unstructured":"Rigothier C.; Delmas Y.; Roumenina L.T.; Contin-Bordes C.; Lepreux S.; Bridoux F.; Goujon J.M.; Bachelet T.; Touchard G.; Fr\u00e9meaux-Bacchi V.; Combe C.; Distal angiopathy and atypical hemolytic uremic syndrome: Clinical and functional properties of an anti\u2013factor H IgA\u03bb antibody. Am J Kidney Dis  2015,66(2),331-336","journal-title":"Am J Kidney Dis"},{"key":"ref=15","doi-asserted-by":"publisher","DOI":"10.2174\/0115733998294022240309105112","volume":"20","author":"Adeva-Andany M.M.","year":"2024","unstructured":"Adeva-Andany M.M.; Carneiro-Freire N.; Castro-Quintela E.; Ameneiros-Rodriguez E.; Adeva-Contreras L.; Fernandez-Fernandez C.; Interferon upregulation associates with insulin resistance in humans. Curr Diabetes Rev  2024,20","journal-title":"Curr Diabetes Rev"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1126\/science.168.3931.596","volume":"168","author":"Beisswenger P.J.","year":"1970","unstructured":"Beisswenger P.J.; Spiro R.G.; Human glomerular basement membrane: Chemical alteration in diabetes mellitus. Science  1970,168(3931),596-598","journal-title":"Science"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.kint.2023.03.039","volume":"104","author":"Laboux T.","year":"2023","unstructured":"Laboux T.; Maanaoui M.; Allain F.; Boulanger E.; Denys A.; Gibier J.B.; Glowacki F.; Grolaux G.; Grunenwald A.; Howsam M.; Lancel S.; Lebas C.; Lopez B.; Roumenina L.; Prov\u00f4t F.; Gnemmi V.; Frimat M.; Hemolysis is associated with altered heparan sulfate of the endothelial glycocalyx and with local complement activation in thrombotic microangiopathies. Kidney Int  2023,104(2),353-366","journal-title":"Kidney Int"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1182\/blood-2015-08-663435","volume":"127","author":"Jodele S.","year":"2016","unstructured":"Jodele S.; Zhang K.; Zou F.; Laskin B.; Dandoy C.E.; Myers K.C.; Lane A.; Meller J.; Medvedovic M.; Chen J.; Davies S.M.; The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood  2016,127(8),989-996","journal-title":"Blood"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"891513","DOI":"10.3389\/fmed.2023.891513","volume":"10","author":"Teoh C.W.","year":"2023","unstructured":"Teoh C.W.; Riedl Khursigara M.; Ortiz-Sandoval C.G.; Park J.W.; Li J.; Bohorquez-Hernandez A.; Bruno V.; Bowen E.E.; Freeman S.A.; Robinson L.A.; Licht C.; The loss of glycocalyx integrity impairs complement factor H binding and contributes to cyclosporine-induced endothelial cell injury. Front Med  2023,10,891513","journal-title":"Front Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S0300-9084(01)01290-1","volume":"83","author":"Spillmann D.","year":"2001","unstructured":"Spillmann D.; Heparan sulfate: Anchor for viral intruders? Biochimie  2001,83(8),811-817","journal-title":"Biochimie"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"e1413","DOI":"10.1002\/cti2.1413","volume":"11","author":"Lo M.W.","year":"2022","unstructured":"Lo M.W.; Amarilla A.A.; Lee J.D.; Albornoz E.A.; Modhiran N.; Clark R.J.; Ferro V.; Chhabra M.; Khromykh A.A.; Watterson D.; Woodruff T.M.; SARS-CoV -2 triggers complement activation through interactions with heparan sulfate. Clin Transl Immunology  2022,11(8),e1413","journal-title":"Clin Transl Immunology"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.kint.2016.07.021","volume":"90","author":"Buob D.","year":"2016","unstructured":"Buob D.; Decambron M.; Gnemmi V.; Frimat M.; Hoffmann M.; Azar R.; Gheerbrant J.D.; Guincestre T.; No\u00ebl C.; Copin M.C.; Glowacki F.; Collapsing glomerulopathy is common in the setting of thrombotic microangiopathy of the native kidney. Kidney Int  2016,90(6),1321-1331","journal-title":"Kidney Int"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/ndt\/gfaa327","volume":"37","author":"Gougeon F.","year":"2022","unstructured":"Gougeon F.; Singh H.K.; Nickeleit V.; Renal comorbidities in collapsing variant focal segmental glomerulosclerosis: More than a coincidence? Nephrol Dial Transplant  2022,37(2),311-317","journal-title":"Nephrol Dial Transplant"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s10875-020-00850-2","volume":"40","author":"Ma M.","year":"2020","unstructured":"Ma M.; Mazumder S.; Kwak H.; Adams M.; Gregory M.; Case report: Acute thrombotic microangiopathy in a patient with sting-associated vasculopathy with onset in infancy (SAVI). J Clin Immunol  2020,40(8),1111-1115","journal-title":"J Clin Immunol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1177\/0961203307082382","volume":"16","author":"Sugimoto T.","year":"2007","unstructured":"Sugimoto T.; Hajiro T.; Fujimoto T.; Kojyo N.; Horie M.; Kashiwagi A.; Letter to the Editor: Thrombotic microangiopathy in an adult patient with clinically amyopathic dermatomyositis complicated with interstitial lung disease. Lupus  2007,16(12),1004-1005","journal-title":"Lupus"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.2169\/internalmedicine.8311-21","volume":"61","author":"Kawamoto S.","year":"2022","unstructured":"Kawamoto S.; Abe T.; Nagahori K.; Yoshino A.; Fujii A.; Ono Y.; Ueda Y.; Takeda T.; Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial pneumonia presenting with nephrotic syndrome during treatment with corticosteroids and cyclosporine. Intern Med  2022,61(13),2007-2012","journal-title":"Intern Med"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/mrcr\/rxac086","volume":"7","author":"Mouri M.","year":"2023","unstructured":"Mouri M.; Kanamori T.; Tanaka E.; Hiratoko K.; Okubo M.; Inoue M.; Morio T.; Shimizu M.; Nishino I.; Okiyama N.; Mori M.; Hepatic veno-occlusive disease accompanied by thrombotic microangiopathy developed during treatment of juvenile dermatomyositis and macrophage activation syndrome: A case report. Mod Rheumatol Case Rep  2023,7(2),404-409","journal-title":"Mod Rheumatol Case Rep"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1038\/sj.ki.5000352","volume":"69","author":"Thaunat O.","year":"2006","unstructured":"Thaunat O.; Delahousse M.; Fakhouri F.; Martinez F.; Stephan J.L.; No\u00ebl L.H.; Karras A.; Nephrotic syndrome associated with hemophagocytic syndrome. Kidney Int  2006,69(10),1892-1898","journal-title":"Kidney Int"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2169\/internalmedicine.9326-17","volume":"57","author":"Omoto S.","year":"2018","unstructured":"Omoto S.; Utsumi T.; Matsuno H.; Terasawa Y.; Iguchi Y.; Thrombotic microangiopathy presenting with intestinal involvement following long-term interferon-\u03b21b treatment for multiple sclerosis. Intern Med  2018,57(5),741-744","journal-title":"Intern Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s10875-020-00789-4","volume":"40","author":"Gloude N.J.","year":"2020","unstructured":"Gloude N.J.; Dandoy C.E.; Davies S.M.; Myers K.C.; Jordan M.B.; Marsh R.A.; Kumar A.; Bleesing J.; Teusink-Cross A.; Jodele S.; Thinking beyond HLH: Clinical features of patients with concurrent presentation of hemophagocytic lymphohistiocytosis and thrombotic microangiopathy. J Clin Immunol  2020,40(5),699-707","journal-title":"J Clin Immunol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/978-1-0716-3175-1_36","volume":"2663","author":"Moore G.W.","year":"2023","unstructured":"Moore G.W.; Vetr H.; Binder N.B.; ADAMTS13 antibody and inhibitor assays. Methods Mol Biol  2023,2663,549-565","journal-title":"Methods Mol Biol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"524","DOI":"10.23876\/j.krcp.22.010","volume":"41","author":"Kim Y.J.","year":"2022","unstructured":"Kim Y.J.; A new pathological perspective on thrombotic microangiopathy. Kidney Res Clin Pract  2022,41(5),524-532","journal-title":"Kidney Res Clin Pract"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0272-6386(97)90575-8","volume":"30","author":"Honda K.","year":"1997","unstructured":"Honda K.; Ando A.; Endo M.; Shimizu K.; Higashihara M.; Nitta K.; Nihei H.; Thrombotic microangiopathy associated with alpha-interferon therapy for chronic myelocytic leukemia. Am J Kidney Dis  1997,30(1),123-130","journal-title":"Am J Kidney Dis"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/S0046-8177(88)80093-5","volume":"19","author":"Richardson S.E.","year":"1988","unstructured":"Richardson S.E.; Karmali M.A.; Becker L.E.; Smith C.R.; The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections. Hum Pathol  1988,19(9),1102-1108","journal-title":"Hum Pathol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.critrevonc.2017.02.011","volume":"112","author":"Kundra A.","year":"2017","unstructured":"Kundra A.; Wang J.C.; Interferon induced thrombotic microangiopathy (TMA): Analysis and concise review. Crit Rev Oncol Hematol  2017,112,103-112","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2583::AID-CNCR14>3.0.CO;2-#","volume":"85","author":"Ravandi-Kashani F.","year":"1999","unstructured":"Ravandi-Kashani F.; Cortes J.; Talpaz M.; Kantarjian H.M.; Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia. Cancer  1999,85(12),2583-2588","journal-title":"Cancer"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1080\/1042819021000055066","volume":"44","author":"Al-Zahrani H.","year":"2003","unstructured":"Al-Zahrani H.; Gupta V.; Minden M.D.; Messner H.A.; Lipton J.H.; Vascular events associated with alpha interferon therapy. Leuk Lymphoma  2003,44(3),471-475","journal-title":"Leuk Lymphoma"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1440-1797.2006.00524.x","volume":"11","author":"Galesic K.","year":"2006","unstructured":"Galesic K.; Bozic B.; Racic I.; Scukanec-Spoljar M.; Thrombotic microangiopathy associated with \u03b1-interferon therapy for chronic myeloid leukaemia (Case Report). Nephrology  2006,11(1),49-52","journal-title":"Nephrology"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/ajh.2830460220","volume":"46","author":"Harvey M.","year":"1994","unstructured":"Harvey M.; Rosenfeld D.; Davies D.; Hall B.M.; Recombinant interferon alpha and hemolytic uremic syndrome: Cause or coincidence? Am J Hematol  1994,46(2),152-153","journal-title":"Am J Hematol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1186\/s12882-022-03034-9","volume":"23","author":"Mei S.","year":"2022","unstructured":"Mei S.; Feng Y.; Cui L.; Chen J.; Mao Z.; Zhao X.; Mei C.; Qian Y.; Thrombotic thrombocytopenic purpura developed after pegylated interferon treatment for hepatitis B infection. BMC Nephrol  2022,23(1),400","journal-title":"BMC Nephrol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12882-023-03200-7","volume":"24","author":"Qin C.","year":"2023","unstructured":"Qin C.; Yin D.; Liu F.; Qiu H.; Thrombotic thrombocytopenic purpura in a patient on long-term alpha-interferon therapy for essential thrombocythemia: A case report. BMC Nephrol  2023,24(1),143","journal-title":"BMC Nephrol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000045147","volume":"80","author":"Ubara Y.","year":"1998","unstructured":"Ubara Y.; Hara S.; Takedatu H.; Katori H.; Yamada K.; Yoshihara K.; Matsushita Y.; Yokoyama K.; Takemoto F.; Yamada A.; Takagawa R.; Endo Y.; Hara M.; Koida I.; Kumada H.; Hemolytic uremic syndrome associated with beta-interferon therapy for chronic hepatitis C. Nephron J  1998,80(1),107-108","journal-title":"Nephron J"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1093\/ckj\/sfab114","volume":"14","author":"Dauvergne M.","year":"2021","unstructured":"Dauvergne M.; Buob D.; Rafat C.; Hennino M.F.; Lemoine M.; Audard V.; Chauveau D.; Ribes D.; Cornec-Le Gall E.; Daugas E.; Pillebout E.; Vuiblet V.; Boffa J.J.; Brocheriou I.; Buob D.; Daniel L.; Doucet L.; Fran\u00e7ois A.; Gnemmi V.; Moktefi A.; Vuiblet V.; Renal diseases secondary to interferon-\u03b2 treatment: A multicentre clinico-pathological study and systematic literature review. Clin Kidney J  2021,14(12),2563-2572","journal-title":"Clin Kidney J"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.ekir.2022.05.002","volume":"7","author":"Taghavi M.","year":"2022","unstructured":"Taghavi M.; Stordeur P.; Collart F.; Dachy B.; Pozdzik A.; Mesquita M.D.C.F.; Nortier J.; Interferon-\u03b21a-induced thrombotic microangiopathy: Possible implication of the alternative pathway of the complement. Kidney Int Rep  2022,7(8),1917-1921","journal-title":"Kidney Int Rep"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3390\/life12010080","volume":"12","author":"Plesa C.F.","year":"2022","unstructured":"Plesa C.F.; Chitimus D.M.; Sirbu C.A.; \u021a\u00e2n\u021bu M.M.; Ghinescu M.C.; Anghel D.; Ionita-Radu F.; Thrombotic thrombocytopenic purpura in interferon beta-1a-treated patient diagnosed with relapsing-remitting multiple sclerosis: A case report. Life  2022,12(1),80","journal-title":"Life"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1111\/bcp.15631","volume":"89","author":"Mrabet S.","year":"2023","unstructured":"Mrabet S.; Dahmane R.; Raja B.; Fradi A.; Aicha N.B.; Sahtout W.; Azzabi A.; Guedri Y.; Zellama D.; Achour A.; Sfar I.; Goucha R.; Abdessayed N.; Mokni M.; Thrombotic microangiopathy due to acquired complement factor I deficiency in a male receiving interferon-beta treatment for multiple sclerosis. Br J Clin Pharmacol  2023,89(5),1682-1685","journal-title":"Br J Clin Pharmacol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1055\/s-2004-830532","volume":"36","author":"Rasmussen M.","year":"2005","unstructured":"Rasmussen M.; Skullerud K.; Bakke S.J.; Lebon P.; Jahnsen F.L.; Cerebral thrombotic microangiopathy and antiphospholipid antibodies in Aicardi-Goutieres syndrome--report of two sisters. Neuropediatrics  2005,36(1),40-44","journal-title":"Neuropediatrics"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"11307","DOI":"10.3390\/ijms231911307","volume":"23","author":"Malgaj V.M.","year":"2022","unstructured":"Malgaj V.M.; Ale\u0161 R.A.; Ve\u010deri\u0107-Haler \u017d.; Coronavirus disease 2019-associated thrombotic microangiopathy: Literature review. Int J Mol Sci  2022,23(19),11307","journal-title":"Int J Mol Sci"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s10238-022-00941-x","volume":"23","author":"Volbeda M.","year":"2022","unstructured":"Volbeda M.; Jou-Valencia D.; van den Heuvel M.C.; Zijlstra J.G.; Franssen C.F.M.; van der Voort P.H.J.; Moser J.; van Meurs M.; Acute and chronic histopathological findings in renal biopsies in COVID-19. Clin Exp Med  2022,23(4),1003-1014","journal-title":"Clin Exp Med"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1097528","DOI":"10.3389\/fmed.2022.1097528","volume":"9","author":"Yamaguchi M.","year":"2023","unstructured":"Yamaguchi M.; Mizuno M.; Kitamura F.; Iwagaitsu S.; Nobata H.; Kinashi H.; Banno S.; Asai A.; Ishimoto T.; Katsuno T.; Ito Y.; Case report: Thrombotic microangiopathy concomitant with macrophage activation syndrome in systemic lupus erythematosus refractory to conventional treatment successfully treated with eculizumab. Front Med  2023,9,1097528","journal-title":"Front Med"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s40620-020-00938-3","volume":"34","author":"Strufaldi F.L.","year":"2021","unstructured":"Strufaldi F.L.; Menezes Neves P.D.M.M.; Dias C.B.; Yu L.; Woronik V.; Cavalcante L.B.; Malheiros D.M.A.C.; Jorge L.B.; Renal thrombotic microangiopathy associated to worse renal prognosis in Lupus Nephritis. J Nephrol  2021,34(4),1147-1156","journal-title":"J Nephrol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00296-022-05182-5","volume":"43","author":"Mutoh T.","year":"2022","unstructured":"Mutoh T.; Ohashi K.; Nagai T.; Sugiura A.; Kudo M.; Fujii H.; Upfront rituximab therapy for thrombotic thrombocytopenic purpura in systemic lupus erythematosus: A case-based review. Rheumatol Int  2022,43(2),373-381","journal-title":"Rheumatol Int"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2169\/internalmedicine.0228-17","volume":"57","author":"Ono M.","year":"2018","unstructured":"Ono M.; Ohashi N.; Namikawa A.; Katahashi N.; Ishigaki S.; Tsuji N.; Isobe S.; Iwakura T.; Sakao Y.; Tsuji T.; Kato A.; Fujigaki Y.; Shimizu A.; Yasuda H.; A rare case of lupus nephritis presenting as thrombotic microangiopathy with diffuse pseudotubulization possibly caused by atypical hemolytic uremic syndrome. Intern Med  2018,57(11),1617-1623","journal-title":"Intern Med"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3389\/fimmu.2019.00487","volume":"10","author":"Palli E.","year":"2019","unstructured":"Palli E.; Kravvariti E.; Tektonidou M.G.; Type I interferon signature in primary antiphospholipid syndrome: Clinical and laboratory associations. Front Immunol  2019,10,487","journal-title":"Front Immunol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1177\/0961203320917460","volume":"29","author":"Skoczynska M.","year":"2020","unstructured":"Skoczynska M.; Crowther M.A.; Chowaniec M.; Ponikowska M.; Chaturvedi S.; Legault K.; Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: Case report and systematic review of the literature. Lupus  2020,29(6),631-639","journal-title":"Lupus"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S0272-6386(12)80543-9","volume":"20","author":"Hughson M.D.","year":"1992","unstructured":"Hughson M.D.; Nadasdy T.; McCarty G.A.; Sholer C.; Min K-W.; Silva F.; Renal thrombotic microangiopathy in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Am J Kidney Dis  1992,20(2),150-158","journal-title":"Am J Kidney Dis"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2023\/7803704","volume":"2023","author":"Komisarof J.","year":"2023","unstructured":"Komisarof J.; Forman J.; Goldman B.; Syposs C.; Passero F.; Garbade E.; A rare case of renal thrombotic microangiopathy and focal segmental glomerulosclerosis secondary to plasma cell leukemia. Case Rep Hematol  2023,2023,1-4","journal-title":"Case Rep Hematol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12882-023-03228-9","volume":"24","author":"Catanese L.","year":"2023","unstructured":"Catanese L.; Link K.; Rupprecht H.; Microangiopathy in multiple myeloma: A case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition. BMC Nephrol  2023,24(1),179","journal-title":"BMC Nephrol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41408-023-00802-0","volume":"13","author":"Moscvin M.","year":"2023","unstructured":"Moscvin M.; Liacos C.I.; Chen T.; Theodorakakou F.; Fotiou D.; Hossain S.; Rowell S.; Leblebjian H.; Regan E.; Czarnecki P.; Bagnoli F.; Bolli N.; Richardson P.; Rennke H.G.; Dimopoulos M.A.; Kastritis E.; Bianchi G.; Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy. Blood Cancer J  2023,13(1),31","journal-title":"Blood Cancer J"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1182\/blood.V78.11.2918.2918","volume":"78","author":"Henter J.I.","year":"1991","unstructured":"Henter J.I.; Elinder G.; S\u00f6der O.; Hansson M.; Andersson B.; Andersson U.; Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood  1991,78(11),2918-2922","journal-title":"Blood"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1365-2141.1994.tb04905.x","volume":"87","author":"Akashi K.","year":"1994","unstructured":"Akashi K.; Hayashi S.; Gondo H.; Mizuno S.; Harada M.; Tamura K.; Yamasaki K.; Shibuya T.; Uike N.; Okamura T.; Miyamoto T.; Niho Y.; Involvement of interferon-\u03b3 and macrophage colony-stimulating factor in pathogenesis of haemophagocytic lymphohistiocytosis in adults. Br J Haematol  1994,87(2),243-250","journal-title":"Br J Haematol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"663329","DOI":"10.3389\/fimmu.2021.663329","volume":"12","author":"Pascarella A.","year":"2021","unstructured":"Pascarella A.; Bracaglia C.; Caiello I.; Arduini A.; Moneta G.M.; Rossi M.N.; Matteo V.; Pardeo M.; De Benedetti F.; Prencipe G.; Monocytes from patients with macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis are hyperresponsive to interferon gamma. Front Immunol  2021,12,663329","journal-title":"Front Immunol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1007\/s10067-023-06594-9","volume":"42","author":"Noboa M.E.R.","year":"2023","unstructured":"Noboa M.E.R.; Lopez-Arevalo H.; Patel A.R.; Arora S.; Manadan A.M.; Nationwide analysis of adult hospitalizations with hemophagocytic lymphohistiocytosis and systemic lupus erythematosus. Clin Rheumatol  2023,42(8),2091-2095","journal-title":"Clin Rheumatol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"977463","DOI":"10.3389\/fimmu.2022.977463","volume":"13","author":"Niizato D.","year":"2022","unstructured":"Niizato D.; Isoda T.; Mitsuiki N.; Kaneko S.; Tomomasa D.; Kamiya T.; Takagi M.; Imai K.; Kajiwara M.; Shimizu M.; Morio T.; Kanegane H.; Case report: Optimized ruxolitinib-based therapy in an infant with familial hemophagocytic lymphohistiocytosis type 3. Front Immunol  2022,13,977463","journal-title":"Front Immunol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1007\/s10067-023-06579-8","volume":"42","author":"Irino K.","year":"2023","unstructured":"Irino K.; Jinnouchi F.; Nakano S.; Sawabe T.; A case of hemophagocytic lymphohistiocytosis with a significant response to baricitinib: A first report with review of literature. Clin Rheumatol  2023,42(7),1959-1963","journal-title":"Clin Rheumatol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"e33803","DOI":"10.1097\/MD.0000000000033803","volume":"102","author":"Li Y.","year":"2023","unstructured":"Li Y.; Li W.; Li Z.; Ma F.; Xu B.; A case report: Hemophagocytic lymphohistiocytosis and thrombotic thrombocytopenic purpura in an otherwise healthy woman. Medicine  2023,102(20),e33803","journal-title":"Medicine"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/archpedi.1971.02100120079010","volume":"121","author":"Leavitt T.J.","year":"1971","unstructured":"Leavitt T.J.; Merigan T.C.; Freeman J.M.; Hemolytic-uremic-like syndrome following polycarboxylate interferon induction. Treatment of Dawson\u2019s inclusion-body encephalitis. Am J Dis Child  1971,121(1),43-47","journal-title":"Am J Dis Child"},{"key":"ref=68","first-page":"ECR34","volume":"91","author":"Kitano K.","year":"2006","unstructured":"Kitano K.; Gibo Y.; Kamijo A.; Furuta K.; Oguchi S.; Joshita S.; Takahashi Y.; Ishida F.; Matsumoto M.; Uemura M.; Fujimura Y.; Thrombotic thrombocytopenic purpura associated with pegylated-interferon alpha-2a by an ADAMTS13 inhibitor in a patient with chronic hepatitis C. Haematologica  2006,91(8),ECR34","journal-title":"Haematologica"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0046-8177(96)90132-X","volume":"27","author":"Crowson A.N.","year":"1996","unstructured":"Crowson A.N.; Magro C.M.; The role of microvascular injury in the pathogenesis of cutaneous lesions of dermatomyositis. Hum Pathol  1996,27(1),15-19","journal-title":"Hum Pathol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/mus.21651","volume":"42","author":"Pestronk A.","year":"2010","unstructured":"Pestronk A.; Schmidt R.E.; Choksi R.; Vascular pathology in dermatomyositis and anatomic relations to myopathology. Muscle Nerve  2010,42(1),53-61","journal-title":"Muscle Nerve"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1001\/archinte.1944.00210160003001","volume":"73","author":"Jager B.V.","year":"1944","unstructured":"Jager B.V.; Grossman L.A.; Dermatomyositis. Arch Intern Med  1944,73(4),271-285","journal-title":"Arch Intern Med"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1007\/s00296-019-04495-2","volume":"40","author":"Day W.","year":"2020","unstructured":"Day W.; Gabriel C.; Kelly R.E.; Magro C.M.; Williams J.V.; Werner A.; Gifford L.; Lapsia S.P.; Aguiar C.L.; Juvenile dermatomyositis resembling late-stage Degos disease with gastrointestinal perforations successfully treated with combination of cyclophosphamide and rituximab: Case-based review. Rheumatol Int  2020,40(11),1883-1890","journal-title":"Rheumatol Int"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"937667","DOI":"10.3389\/fimmu.2022.937667","volume":"13","author":"Tonutti A.","year":"2022","unstructured":"Tonutti A.; Motta F.; Ceribelli A.; Isailovic N.; Selmi C.; De Santis M.; Anti-MDA5 antibody linking COVID-19, type I interferon, and autoimmunity: A case report and systematic literature review. Front Immunol  2022,13,937667","journal-title":"Front Immunol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ana.20464","volume":"57","author":"Greenberg S.A.","year":"2005","unstructured":"Greenberg S.A.; Pinkus J.L.; Pinkus G.S.; Burleson T.; Sanoudou D.; Tawil R.; Barohn R.J.; Saperstein D.S.; Briemberg H.R.; Ericsson M.; Park P.; Amato A.A.; Interferon-\u03b1\/\u03b2-mediated innate immune mechanisms in dermatomyositis. Ann Neurol  2005,57(5),664-678","journal-title":"Ann Neurol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/bjd.15006","volume":"176","author":"Huard C.","year":"2017","unstructured":"Huard C.; Gull\u00e0 S.V.; Bennett D.V.; Coyle A.J.; Vleugels R.A.; Greenberg S.A.; Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon \u03b2 in dermatomyositis. Br J Dermatol  2017,176(5),1224-1230","journal-title":"Br J Dermatol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/bjd.16917","volume":"180","author":"Zhang S.H.","year":"2019","unstructured":"Zhang S.H.; Zhao Y.; Xie Q.B.; Jiang Y.; Wu Y.K.; Yan B.; Aberrant activation of the type I interferon system may contribute to the pathogenesis of anti-melanoma differentiation-associated gene 5 dermatomyositis. Br J Dermatol  2019,180(5),1090-1098","journal-title":"Br J Dermatol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1093\/rheumatology\/key386","volume":"58","author":"Ono N.","year":"2019","unstructured":"Ono N.; Kai K.; Maruyama A.; Sakai M.; Sadanaga Y.; Koarada S.; Inoue T.; Tada Y.; The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients. Rheumatology  2019,58(5),786-791","journal-title":"Rheumatology"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1002\/art.42526","volume":"75","author":"Tabata M.M.","year":"2023","unstructured":"Tabata M.M.; Hodgkinson L.M.; Wu T.T.; Li S.; Huard C.; Zhao S.; Bennett D.; Johnson J.; Tierney C.; He W.; Buhlmann J.E.; Page K.M.; Johnson K.; Casciola-Rosen L.; Chung L.; Sarin K.Y.; Fiorentino D.; The type I interferon signature reflects multiple phenotypic and activity measures in dermatomyositis. Arthritis Rheumatol  2023,75(10),1842-1849","journal-title":"Arthritis Rheumatol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1151695","DOI":"10.3389\/fimmu.2023.1151695","volume":"14","author":"Qian J.","year":"2023","unstructured":"Qian J.; Li R.; Chen Z.; Cao Z.; Lu L.; Fu Q.; Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients. Front Immunol  2023,14,1151695","journal-title":"Front Immunol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.clim.2006.05.011","volume":"120","author":"O\u2019Connor K.A.","year":"2006","unstructured":"O\u2019Connor K.A.; Abbott K.A.; Sabin B.; Kuroda M.; Pachman L.M.; MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: Association with muscle involvement. Clin Immunol  2006,120(3),319-325","journal-title":"Clin Immunol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1136\/ard.2010.139949","volume":"70","author":"Liao A.P.","year":"2011","unstructured":"Liao A.P.; Salajegheh M.; Nazareno R.; Kagan J.C.; Jubin R.G.; Greenberg S.A.; Interferon is associated with type 1 interferon-inducible gene expression in dermatomyositis. Ann Rheum Dis  2011,70(5),831-836","journal-title":"Ann Rheum Dis"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/art.40800","volume":"71","author":"Moneta G.M.","year":"2019","unstructured":"Moneta G.M.; Pires Marafon D.; Marasco E.; Rosina S.; Verardo M.; Fiorillo C.; Minetti C.; Bracci-Laudiero L.; Ravelli A.; De Benedetti F.; Nicolai R.; Muscle expression of type I and type  interferons is increased in juvenile dermatomyositis and related to clinical and histologic features. Arthritis Rheumatol  2019,71(6),1011-1021","journal-title":"Arthritis Rheumatol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3109\/14397595.2014.900843","volume":"25","author":"Horai Y.","year":"2015","unstructured":"Horai Y.; Koga T.; Fujikawa K.; Takatani A.; Nishino A.; Nakashima Y.; Suzuki T.; Kawashiri S.; Iwamoto N.; Ichinose K.; Tamai M.; Nakamura H.; Ida H.; Kakugawa T.; Sakamoto N.; Ishimatsu Y.; Mukae H.; Hamaguchi Y.; Fujimoto M.; Kuwana M.; Origuchi T.; Kohno S.; Kawakami A.; Serum interferon-\u03b1 is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis. Mod Rheumatol  2015,25(1),85-89","journal-title":"Mod Rheumatol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/BF02826219","volume":"17","author":"Dietrich L.L.","year":"2000","unstructured":"Dietrich L.L.; Bridges A.J.; Albertini M.R.; Dermatomyositis after interferon alpha treatment. Med Oncol  2000,17(1),64-69","journal-title":"Med Oncol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1080\/14397595.2018.1548918","volume":"29","author":"Nishioka A.","year":"2019","unstructured":"Nishioka A.; Tsunoda S.; Abe T.; Yoshikawa T.; Takata M.; Kitano M.; Matsui K.; Nakashima R.; Hosono Y.; Ohmura K.; Mimori T.; Sano H.; Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody- positive dermatomyositis. Mod Rheumatol  2019,29(5),814-820","journal-title":"Mod Rheumatol"},{"key":"ref=86","first-page":"275","volume":"41","author":"Kokuzawa A.","year":"2023","unstructured":"Kokuzawa A.; Nakamura J.; Kamata Y.; Sato K.; Potential role of type I interferon\/IP-10 axis in the pathogenesis of anti-MDA5 antibody-positive dermatomyositis. Clin Exp Rheumatol  2023,41(2),275-284","journal-title":"Clin Exp Rheumatol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s13075-018-1737-2","volume":"20","author":"Ishikawa Y.","year":"2018","unstructured":"Ishikawa Y.; Iwata S.; Hanami K.; Nawata A.; Zhang M.; Yamagata K.; Hirata S.; Sakata K.; Todoroki Y.; Nakano K.; Nakayamada S.; Satoh M.; Tanaka Y.; Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis. Arthritis Res Ther  2018,20(1),240","journal-title":"Arthritis Res Ther"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1056\/NEJM198602063140601","volume":"314","author":"Kissel J.T.","year":"1986","unstructured":"Kissel J.T.; Mendell J.R.; Rammohan K.W.; Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med  1986,314(6),329-334","journal-title":"N Engl J Med"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1093\/brain\/aww122","volume":"139","author":"Lahoria R.","year":"2016","unstructured":"Lahoria R.; Selcen D.; Engel A.G.; Microvascular alterations and the role of complement in dermatomyositis. Brain  2016,139(7),1891-1903","journal-title":"Brain"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/bjd.12642","volume":"170","author":"Theodoridis A.","year":"2014","unstructured":"Theodoridis A.; Konstantinidou A.; Makrantonaki E.; Zouboulis C.C.; Malignant and benign forms of atrophic papulosis (K\u00f6hlmeier-Degos disease): Systemic involvement determines the prognosis. Br J Dermatol  2014,170(1),110-115","journal-title":"Br J Dermatol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1309\/AJCP66QIMFARLZKI","volume":"135","author":"Magro C.M.","year":"2011","unstructured":"Magro C.M.; Poe J.C.; Kim C.; Shapiro L.; Nuovo G.; Crow M.K.; Crow Y.J.; Degos disease. Am J Clin Pathol  2011,135(4),599-610","journal-title":"Am J Clin Pathol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/1346-8138.16727","volume":"50","author":"Honda K.Y.","year":"2023","unstructured":"Honda K.Y.; Otsuka A.; Kogame T.; Ito H.; Usui S.; Fujimoto M.; Jinnouchi K.; Hirata M.; Sugiura K.; Kabashima K.; Increased type I interferon expression from T cells in lesional skin of Degos disease. J Dermatol  2023,50(5),720-722","journal-title":"J Dermatol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/bjd.12773","volume":"170","author":"Zaharia D.","year":"2014","unstructured":"Zaharia D.; Truchot F.; Ronger-Savle S.; Balme B.; Thomas L.; Benign form of atrophic papulosis developed at injection sites of pegylated-alpha-interferon: is there a pathophysiological link? Br J Dermatol  2014,170(4),992-994","journal-title":"Br J Dermatol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S1474-4422(22)00167-3","volume":"21","author":"Becker L.L.","year":"2022","unstructured":"Becker L.L.; Ebstein F.; Horn D.; Zouboulis C.C.; Kr\u00fcger E.; Kaindl A.M.; Tietze A.; Eger A.; Kallinich T.; Biskup S.; Schmid S.; Stenzel W.; M\u00fcnzfeld H.; Blume-Peytavi U.; Interferon receptor dysfunction in a child with malignant atrophic papulosis and CNS involvement. Lancet Neurol  2022,21(8),682-686","journal-title":"Lancet Neurol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"S481","DOI":"10.1542\/peds.2016-4206","volume":"141","author":"Huang Y.C.","year":"2018","unstructured":"Huang Y.C.; Wang J.D.; Lee F.Y.; Fu L.S.; Pediatric malignant atrophic papulosis. Pediatrics  2018,141(Suppl. 5),S481-S484","journal-title":"Pediatrics"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0002-9343(60)90018-8","volume":"29","author":"Clarkson B.","year":"1960","unstructured":"Clarkson B.; Thompson D.; Horwith M.; Luckey E.H.; Cyclical edema and shock due to increased capillary permeability. Am J Med  1960,29(2),193-216","journal-title":"Am J Med"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s10067-012-1940-5","volume":"31","author":"Wang D.X.","year":"2012","unstructured":"Wang D.X.; Shu X.M.; Tian X.L.; Chen F.; Zu N.; Ma L.; Wang G.C.; Intravenous immunoglobulin therapy in adult patients with polymyositis\/dermatomyositis: A systematic literature review. Clin Rheumatol  2012,31(5),801-806","journal-title":"Clin Rheumatol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1177\/02676591211057510","volume":"38","author":"Ling S.K.","year":"2023","unstructured":"Ling S.K.; Fong N.M.; Chan M.S.; A case of recurrent systemic capillary leak syndrome triggered by influenza A infection associated with cardiogenic shock supported by veno-arterial extracorporeal membrane oxygenation. Perfusion  2023,38(2),428-431","journal-title":"Perfusion"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"104309","DOI":"10.1016\/j.amsu.2022.104309","volume":"81","author":"Younus S.","year":"2022","unstructured":"Younus S.; Maqsood H.; An unusual presentation of recurrent COVID-19 associated systemic capillary leak syndrome in a patient with multi-system inflammatory syndrome in adults (MIS-A) due to prior COVID-19 infection: Case report and literature review. Ann Med Surg  2022,81,104309","journal-title":"Ann Med Surg"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/00005792-197705000-00004","volume":"56","author":"Atkinson J.P.","year":"1977","unstructured":"Atkinson J.P.; Waldmann T.A.; Stein S.F.; Gelfand J.A.; Macdonald W.J.; Heck L.W.; Cohen E.L.; Kaplan A.P.; Frank M.M.; Systemic capillary leak syndrome and monoclonal IgG gammopathy; studies in a sixth patient and a review of the literature. Medicine  1977,56(3),225-239","journal-title":"Medicine"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.2169\/internalmedicine.34.1220","volume":"34","author":"Hiraoka E.","year":"1995","unstructured":"Hiraoka E.; Matsushima Y.; Inomoto-Naribayashi Y.; Nakata H.; Nakamura A.; Kawanami C.; Kinoshita Y.; Isobe T.; Chiba T.; Systemic capillary leak syndrome associated with multiple myeloma of IgG kappa type. Intern Med  1995,34(12),1220-1224","journal-title":"Intern Med"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1212\/WNL.53.1.220","volume":"53","author":"Schmidt S.","year":"1999","unstructured":"Schmidt S.; Hertfelder H.J.; von Spiegel T.; Hering R.; Harzheim M.; Lassmann H.; Deckert-Schl\u00fcter M.; Schlegel U.; Lethal capillary leak syndrome after a single administration of interferon beta-1b. Neurology  1999,53(1),220-222","journal-title":"Neurology"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/archinte.162.4.481","volume":"162","author":"Yamamoto K.","year":"2002","unstructured":"Yamamoto K.; Mizuno M.; Tsuji T.; Amano T.; Capillary leak syndrome after interferon treatment for chronic hepatitis C. Arch Intern Med  2002,162(4),481-482","journal-title":"Arch Intern Med"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jaip.2022.10.023","volume":"11","author":"Druey K.M.","year":"2023","unstructured":"Druey K.M.; Eisch A.R.; Cunningham-Rundles C.; Autologous hematopoietic stem cell transplantation in Clarkson disease. J Allergy Clin Immunol Pract  2023,11(1),347-349","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref=105","first-page":"1000213","volume":"5","author":"Xie Z.","year":"2014","unstructured":"Xie Z.; Chan E.; Yin Y.; Ghosh C.C.; Wisch L.; Nelson C.; Young M.; Parikh S.M.; Druey K.M.; Inflammatory markers of the systemic capillary leak syndrome (Clarkson disease). J Clin Cell Immunol  2014,5,1000213","journal-title":"J Clin Cell Immunol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"152028","DOI":"10.1016\/j.anndiagpath.2022.152028","volume":"61","author":"Magro C.M.","year":"2022","unstructured":"Magro C.M.; Mo J.H.; Pecker M.S.; Idiopathic systemic capillary leak syndrome, a unique complement and interferon mediated endotheliopathy syndrome: The role of the normal skin biopsy in establishing the diagnosis and elucidating pathogenetic mechanisms. Ann Diagn Pathol  2022,61,152028","journal-title":"Ann Diagn Pathol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/BF01697978","volume":"71","author":"Salat C.","year":"1995","unstructured":"Salat C.; Holler E.; Schleuning M.; Eisele B.; Reinhardt B.; Kolb H.; Pihusch R.; Domrath R.; Hiller E.; Levels of the terminal complement complex, C3a-desArg and C1-inhibitor in adult patients with capillary leak syndrome following bone marrow transplantation. Ann Hematol  1995,71(6),271-274","journal-title":"Ann Hematol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"423","DOI":"10.7326\/0003-4819-125-5-199609010-00025","volume":"125","author":"Creutzig A.","year":"1996","unstructured":"Creutzig A.; Caspary L.; Freund M.; The Raynaud phenomenon and interferon therapy. Ann Intern Med  1996,125(5),423","journal-title":"Ann Intern Med"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3747\/co.v17i4.519","volume":"17","author":"Husein-ElAhmed H.","year":"2010","unstructured":"Husein-ElAhmed H.; Callejas-Rubio J.L.; Del Olmo R.O.; R\u00edos-Fernandez R.; Ortego-Centeno N.; Severe Raynaud syndrome induced by adjuvant interferon alfa in metastatic melanoma. Curr Oncol  2010,17(4),122-123","journal-title":"Curr Oncol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"577918","DOI":"10.3389\/fped.2020.577918","volume":"8","author":"Dai Y.","year":"2020","unstructured":"Dai Y.; Liu X.; Zhao Z.; He J.; Yin Q.; Stimulator of interferon genes-associated vasculopathy with onset in infancy: A systematic review of case reports. Front Pediatr  2020,8,577918","journal-title":"Front Pediatr"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1001\/jamadermatol.2014.3438","volume":"151","author":"G\u00fcnther C.","year":"2015","unstructured":"G\u00fcnther C.; Berndt N.; Wolf C.; Lee-Kirsch M.A.; Familial chilblain lupus due to a novel mutation in the exonuclease III domain of 3\u2032 repair exonuclease 1 (TREX1). JAMA Dermatol  2015,151(4),426-431","journal-title":"JAMA Dermatol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.jaad.2020.06.1018","volume":"83","author":"Battesti G.","year":"2020","unstructured":"Battesti G.; El Khalifa J.; Abdelhedi N.; Ferre V.; Bouscarat F.; Picard-Dahan C.; Brunet-Possenti F.; Collin G.; Lavaud J.; Le Bozec P.; Rousselot M.; Tournier A.; Lheure C.; Couvelard A.; Hacein-Bey-Abina S.; Abina A.M.; Charpentier C.; Mignot S.; Nicaise P.; Descamps D.; Deschamps L.; Descamps V.; New insights in COVID-19\u2013associated chilblains: A comparative study with chilblain lupus erythematosus. J Am Acad Dermatol  2020,83(4),1219-1222","journal-title":"J Am Acad Dermatol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1111\/jdv.18582","volume":"37","author":"Blau K.","year":"2023","unstructured":"Blau K.; Lehr S.; Aschoff R.; Al Gburi S.; Br\u00fcck N.; Chapsa M.; Schnabel A.; Abraham S.; J\u00f6hrens K.; Beissert S.; G\u00fcnther C.; Course and outcome of chilblain-like acral lesions during  -19 pandemic. J Eur Acad Dermatol Venereol  2023,37(1),e29-e31","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.clindermatol.2022.09.010","volume":"41","author":"Starkey S.Y.","year":"2023","unstructured":"Starkey S.Y.; Mar K.; Kashetsky N.; Lam J.M.; Dutz J.; Mukovozov I.; Chilblain-like lesions coinciding with the SARS-CoV-2 pandemic. Clin Dermatol  2023,41(1),223-229","journal-title":"Clin Dermatol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/dermatopathology7030010","volume":"7","author":"Aschoff R.","year":"2020","unstructured":"Aschoff R.; Zimmermann N.; Beissert S.; G\u00fcnther C.; Type I interferon signature in chilblain-like lesions associated with the COVID-19 pandemic. Dermatopathology  2020,7(3),57-63","journal-title":"Dermatopathology"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/bjd.19415","volume":"184","author":"Magro C.M.","year":"2021","unstructured":"Magro C.M.; Mulvey J.J.; Laurence J.; Sanders S.; Crowson A.N.; Grossman M.; Harp J.; Nuovo G.; The differing pathophysiologies that underlie COVID-19-associated perniosis and thrombotic retiform purpura: A case series. Br J Dermatol  2021,184(1),141-150","journal-title":"Br J Dermatol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1001\/jamadermatol.2020.4324","volume":"157","author":"Hubiche T.","year":"2021","unstructured":"Hubiche T.; Cardot-Leccia N.; Le Duff F.; Seitz-Polski B.; Giordana P.; Chiaverini C.; Giordanengo V.; Gonfrier G.; Raimondi V.; Bausset O.; Adjtoutah Z.; Garnier M.; Burel-Vandenbos F.; Dadone-Montaudi\u00e9 B.; Fassbender V.; Palladini A.; Courjon J.; Mondain V.; Contenti J.; Dellamonica J.; Leftheriotis G.; Passeron T.; Clinical, laboratory, and interferon-alpha response characteristics of patients with chilblain-like lesions during the COVID-19 pandemic. JAMA Dermatol  2021,157(2),202-206","journal-title":"JAMA Dermatol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/bjd.20707","volume":"185","author":"Frumholtz L.","year":"2021","unstructured":"Frumholtz L.; Bouaziz J.D.; Battistella M.; Hadjadj J.; Chocron R.; Bengoufa D.; Le Buanec H.; Barnabei L.; Meynier S.; Schwartz O.; Grzelak L.; Smith N.; Charbit B.; Duffy D.; Yatim N.; Calugareanu A.; Philippe A.; Guerin C.L.; Joly B.; Siguret V.; Jaume L.; Bachelez H.; Bagot M.; Rieux-Laucat F.; Maylin S.; Legoff J.; Delaugerre C.; Gendron N.; Smadja D.M.; Cassius C.; Type I interferon response and vascular alteration in chilblain-like lesions during the COVID-19 outbreak. Br J Dermatol  2021,185(6),1176-1185","journal-title":"Br J Dermatol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"897500","DOI":"10.3389\/fimmu.2022.897500","volume":"13","author":"Eugster A.","year":"2022","unstructured":"Eugster A.; M\u00fcller D.; Gompf A.; Reinhardt S.; Lindner A.; Ashton M.; Zimmermann N.; Beissert S.; Bonifacio E.; G\u00fcnther C.; A novel type I interferon primed dendritic cell subpopulation in TREX1 mutant chilblain lupus patients. Front Immunol  2022,13,897500","journal-title":"Front Immunol"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jamadermatol.2015.0251","volume":"151","author":"Munoz J.","year":"2015","unstructured":"Munoz J.; Rodi\u00e8re M.; Jeremiah N.; Rieux-Laucat F.; Oojageer A.; Rice G.I.; Rozenberg F.; Crow Y.J.; Bessis D.; Stimulator of interferon genes\u2013associated vasculopathy with onset in infancy. JAMA Dermatol  2015,151(8),872-877","journal-title":"JAMA Dermatol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S0272-6386(86)80052-X","volume":"7","author":"Weiss M.A.","year":"1986","unstructured":"Weiss M.A.; Daquioag E.; Margolin E.G.; Pollak V.E.; Nephrotic syndrome, progressive irreversible renal failure, and glomerular \u201ccollapse\u201d: A new clinicopathologic entity? Am J Kidney Dis  1986,7(1),20-28","journal-title":"Am J Kidney Dis"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.xkme.2020.05.005","volume":"2","author":"Sharma Y.","year":"2020","unstructured":"Sharma Y.; Nasr S.H.; Larsen C.P.; Kemper A.; Ormsby A.H.; Williamson S.R.; COVID-19\u2013associated collapsing focal segmental glomerulosclerosis: A report of 2 cases. Kidney Med  2020,2(4),493-497","journal-title":"Kidney Med"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1023\/A:1005638913487","volume":"46","author":"Stein D.F.","year":"2001","unstructured":"Stein D.F.; Ahmed A.; Sunkhara V.; Khalbuss W.; Collapsing focal segmental glomerulosclerosis with recovery of renal function: An uncommon complication of interferon therapy for hepatitis C. Dig Dis Sci  2001,46(3),530-535","journal-title":"Dig Dis Sci"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s11255-009-9594-1","volume":"42","author":"Kanungo S.","year":"2010","unstructured":"Kanungo S.; Tamirisa S.; Gopalakrishnan R.; Salinas-Madrigal L.; Bastani B.; Collapsing glomerulopathy as a complication of interferon therapy for hepatitis C infection. Int Urol Nephrol  2010,42(1),219-222","journal-title":"Int Urol Nephrol"},{"key":"ref=125","first-page":"564","volume":"3","author":"Berdichevski R.H.","year":"2010","unstructured":"Berdichevski R.H.; De Carvalho E.M.; Edelweiss M.I.; Gon\u00e7alves L.F.; Manfro R.C.; Collapsing glomerulopathy after hepatitis C pegylated interferon treatment. Recovery of renal function with high-dose steroid treatment. NDT Plus  2010,3(6),564-566","journal-title":"NDT Plus"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2215\/CJN.07311009","volume":"5","author":"Markowitz G.S.","year":"2010","unstructured":"Markowitz G.S.; Nasr S.H.; Stokes M.B.; D\u2019Agati V.D.; Treatment with IFN-alpha, -beta, or -gamma is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol  2010,5(4),607-615","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/ki.2014.270","volume":"87","author":"Nichols B.","year":"2015","unstructured":"Nichols B.; Jog P.; Lee J.H.; Blackler D.; Wilmot M.; D\u2019Agati V.; Markowitz G.; Kopp J.B.; Alper S.L.; Pollak M.R.; Friedman D.J.; Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1. Kidney Int  2015,87(2),332-342","journal-title":"Kidney Int"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1053\/j.ajkd.2021.02.330","volume":"78","author":"Fenaroli P.","year":"2021","unstructured":"Fenaroli P.; Rossi G.M.; Angelotti M.L.; Antonelli G.; Volpi S.; Grossi A.; Delsante M.; Lodi L.; Landini S.; Romagnani P.; Vaglio A.; Collapsing glomerulopathy as a complication of type I interferon\u2013mediated glomerulopathy in a patient with RNASEH2B-related aicardi-gouti\u00e8res syndrome. Am J Kidney Dis  2021,78(5),750-754","journal-title":"Am J Kidney Dis"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1191\/0961203305lu2162cr","volume":"14","author":"Marques L.P.","year":"2005","unstructured":"Marques L.P.; Pacheco G.G.; Rioja L.S.; Nunes S.N.; Velone S.T.; Santos O.R.; Can systemic lupus erythematosus be the cause of collapsing glomerulopathy? Lupus  2005,14(10),853-855","journal-title":"Lupus"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"bcr-2018-227860","DOI":"10.1136\/bcr-2018-227860","volume":"12","author":"Chokshi B.","year":"2019","unstructured":"Chokshi B.; D\u2019Agati V.; Bizzocchi L.; Johnson B.; Mendez B.; Jim B.; Haemophagocytic lymphohistiocytosis with collapsing lupus podocytopathy as an unusual manifestation of systemic lupus erythematosus with APOL1 double-risk alleles. BMJ Case Rep  2019,12(1),bcr-2018-227860","journal-title":"BMJ Case Rep"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000510840","volume":"11","author":"Vanood A.","year":"2021","unstructured":"Vanood A.; Owen R.; Maraskine M.; Schreiber A.; Pokharel R.; Cohen L.; Collapsing FSGS with concurrent class 2 and 3 lupus nephritis: A case report and review of the literature. Case Rep Nephrol Dial  2021,11(1),16-25","journal-title":"Case Rep Nephrol Dial"},{"key":"ref=132","first-page":"27","volume":"65","author":"Winston J.","year":"1998","unstructured":"Winston J.; Klotman P.E.; HIV-associated nephropathy. Mt Sinai J Med  1998,65(1),27-32","journal-title":"Mt Sinai J Med"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"110","DOI":"10.5414\/CNCS111112","volume":"11","author":"Gandhi P.","year":"2023","unstructured":"Gandhi P.; Dowling C.S.; Satoskar A.; Shah A.; Successful treatment of COVID-19-associated collapsing glomerulopathy: 22 months of follow-up. Clin Nephrol Case Stud  2023,11(1),110-113","journal-title":"Clin Nephrol Case Stud"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"e23175","DOI":"10.7759\/cureus.23175","volume":"14","author":"Wiggins B.","year":"2022","unstructured":"Wiggins B.; Deliwala S.; Banno F.; Knight K.; Minaudo M.; Acute renal failure and nephrotic syndrome secondary to collapsing glomerulopathy associated with hepatitis C. Cureus  2022,14(3),e23175","journal-title":"Cureus"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1046\/j.1523-1755.2001.00727.x","volume":"59","author":"Moudgil A.","year":"2001","unstructured":"Moudgil A.; Nast C.C.; Bagga A.; Wei L.; Nurmamet A.; Cohen A.H.; Jordan S.C.; Toyoda M.; Association of parvovirus B19 infection with idiopathic collapsing glomerulopathy. Kidney Int  2001,59(6),2126-2133","journal-title":"Kidney Int"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1093\/ckj\/sfs059","volume":"5","author":"Joshi A.","year":"2012","unstructured":"Joshi A.; Arora A.; Cimbaluk D.; Dunea G.; Hart P.; Acute epstein-barr virus infection-associated collapsing glomerulopathy. Clin Kidney J  2012,5(4),320-322","journal-title":"Clin Kidney J"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/ckj\/sfs097","volume":"6","author":"Grover V.","year":"2013","unstructured":"Grover V.; Gaiki M.R.; DeVita M.V.; Schwimmer J.A.; Cytomegalovirus-induced collapsing focal segmental glomerulosclerosis. Clin Kidney J  2013,6(1),71-73","journal-title":"Clin Kidney J"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.3892\/etm.2016.3161","volume":"11","author":"Zhu X.","year":"2016","unstructured":"Zhu X.; Liu H.; Yuan S.; Xu X.; Dong Z.; Liu F.; Collapsing glomerulopathy with rare associated coxsackie virus infection: A case report. Exp Ther Med  2016,11(5),1871-1874","journal-title":"Exp Ther Med"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/ckj\/sfy104","volume":"12","author":"Ara\u00fajo S.A.","year":"2019","unstructured":"Ara\u00fajo S.A.; Cordeiro T.M.; Belis\u00e1rio A.R.; Ara\u00fajo R.F.A.; Marinho P.E.S.; Kroon E.G.; de Oliveira D.B.; Teixeira M.M.; Sim\u00f5es e Silva A.C.; First report of collapsing variant of focal segmental glomerulosclerosis triggered by arbovirus: Dengue and Zika virus infection. Clin Kidney J  2019,12(3),355-361","journal-title":"Clin Kidney J"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s10024-003-3027-4","volume":"7","author":"Coventry S.","year":"2004","unstructured":"Coventry S.; Shoemaker L.R.; Collapsing glomerulopathy in a 16-year-old girl with pulmonary tuberculosis: the role of systemic inflammatory mediators. Pediatr Dev Pathol  2004,7(2),166-170","journal-title":"Pediatr Dev Pathol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"964","DOI":"10.2215\/CJN.00590120","volume":"15","author":"Amoura A.","year":"2020","unstructured":"Amoura A.; Moktefi A.; Halfon M.; Karras A.; Rafat C.; Gibier J.B.; Gleeson P.J.; Servais A.; Argy N.; Maill\u00e9 P.; Belenfant X.; Gueutin V.; Delpierre A.; Tricot L.; El Karoui K.; Jourde-Chiche N.; Houze S.; Sahali D.; Audard V.; Malaria, collapsing glomerulopathy, and focal and segmental glomerulosclerosis. Clin J Am Soc Nephrol  2020,15(7),964-972","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"e0008582","DOI":"10.1371\/journal.pntd.0008582","volume":"14","author":"Neves P.D.","year":"2020","unstructured":"Neves P.D.; Bridi R.A.; Ramalho J.A.; Jorge L.B.; Watanabe E.H.; Watanabe A.; Yu L.; Woronik V.; Pinheiro R.B.; Testagrossa L.A.; Cavalcante L.B.; Malheiros D.M.; Dias C.B.; Onuchic L.F.; Schistosoma mansoni infection as a trigger to collapsing glomerulopathy in a patient with high-risk APOL1 genotype. PLoS Negl Trop Dis  2020,14(10),e0008582","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1681\/ASN.2021070931","volume":"32","author":"Kudose S.","year":"2021","unstructured":"Kudose S.; Santoriello D.; Bomback A.S.; Sekulic M.; Batal I.; Stokes M.B.; Ghavami I.A.; Kim J.S.; Marasa M.; Xu K.; Peleg Y.; Barasch J.; Canetta P.; Rasouly H.M.; Gharavi A.G.; Markowitz G.S.; D\u2019Agati V.D.; Longitudinal outcomes of COVID-19\u2013associated collapsing glomerulopathy and other podocytopathies. J Am Soc Nephrol  2021,32(11),2958-2969","journal-title":"J Am Soc Nephrol"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000510759","volume":"145","author":"Lohani S.","year":"2021","unstructured":"Lohani S.; Sadasivam M.; Rabb H.; Atta M.G.; Persistent interferon production by double negative T cells and collapsing focal segmental glomerulosclerosis. Nephron J  2021,145(1),85-90","journal-title":"Nephron J"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40248-016-0082-z","volume":"12","author":"Papani R.","year":"2017","unstructured":"Papani R.; Duarte A.G.; Lin Y.; Kuo Y.F.; Sharma G.; Pulmonary arterial hypertension associated with interferon therapy: A population-based study. Multidiscip Respir Med  2017,12(1),1","journal-title":"Multidiscip Respir Med"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s002770100298","volume":"80","author":"Fruehauf S.","year":"2001","unstructured":"Fruehauf S.; Steiger S.; Topaly J.; Ho A.; Pulmonary artery hypertension during interferon-\u03b1 therapy for chronic myelogenous leukemia. Ann Hematol  2001,80(5),308-310","journal-title":"Ann Hematol"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.2169\/internalmedicine.56.7822","volume":"56","author":"Tsuchiya H.","year":"2017","unstructured":"Tsuchiya H.; Kioka H.; Ozu K.; Ohtani T.; Yamaguchi O.; Yazaki Y.; Yamauchi-Takihara K.; Sakata Y.; Interferon therapy exacerbated pulmonary hypertension in a patient with hepatitis C virus infection: Pathogenic interplay among multiple risk factors. Intern Med  2017,56(9),1061-1065","journal-title":"Intern Med"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1177\/1352458509104593","volume":"15","author":"Ledinek A.H.","year":"2009","unstructured":"Ledinek A.H.; Jazbec S.\u0160.; Drinovec I.; Rot U.; Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: A case report. Mult Scler  2009,15(7),885-886","journal-title":"Mult Scler"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.jaccas.2021.02.005","volume":"3","author":"Raza F.","year":"2021","unstructured":"Raza F.; Kozitza C.; Chybowski A.; Goss K.N.; Berei T.; Runo J.; Eldridge M.; Chesler N.; Interferon-\u03b2\u2013induced pulmonary arterial hypertension. JACC Case Rep  2021,3(7),1038-1043","journal-title":"JACC Case Rep"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3389\/fimmu.2020.00985","volume":"11","author":"Zheng S.","year":"2020","unstructured":"Zheng S.; Lee P.Y.; Wang J.; Wang S.; Huang Q.; Huang Y.; Liu Y.; Zhou Q.; Li T.; Interstitial lung disease and psoriasis in a child with aicardi-gouti\u00e8res syndrome. Front Immunol  2020,11,985","journal-title":"Front Immunol"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"103335","DOI":"10.1016\/j.autrev.2023.103335","volume":"22","author":"Wang H.","year":"2023","unstructured":"Wang H.; Lv J.; He J.; Wu W.; Zhong Y.; Cao S.; Cai Y.; Wang Q.; The prevalence and effects of treatments of rapidly progressive interstitial lung disease of dermatomyositis\/polymyositis adults: A systematic review and meta-analysis. Autoimmun Rev  2023,22(8),103335","journal-title":"Autoimmun Rev"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"1146904","DOI":"10.3389\/fimmu.2023.1146904","volume":"14","author":"Wu Y.","year":"2023","unstructured":"Wu Y.; Li Y.; Luo Y.; Zhou Y.; Liang X.; Cheng L.; Wu T.; Wen J.; Tan C.; Liu Y.; Proteomics: Potential techniques for discovering the pathogenesis of connective tissue diseases-interstitial lung disease. Front Immunol  2023,14,1146904","journal-title":"Front Immunol"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.hfc.2022.08.016","volume":"19","author":"Lewis C.","year":"2023","unstructured":"Lewis C.; Sanderson R.; Vasilottos N.; Zheutlin A.; Visovatti S.; Pulmonary arterial hypertension in connective tissue diseases beyond systemic sclerosis. Heart Fail Clin  2023,19(1),45-54","journal-title":"Heart Fail Clin"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"892","DOI":"10.21037\/cdt-20-429","volume":"10","author":"Wang X.","year":"2020","unstructured":"Wang X.; Tu Y.; Huang B.; Li Y.; Li Y.; Zhang S.; Lin Y.; Huang L.; Zhang W.; Luo H.; Pulmonary vascular endothelial injury and acute pulmonary hypertension caused by COVID-19: The fundamental cause of refractory hypoxemia? Cardiovasc Diagn Ther  2020,10(4),892-897","journal-title":"Cardiovasc Diagn Ther"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"623430","DOI":"10.3389\/fimmu.2021.623430","volume":"12","author":"Fraser E.","year":"2021","unstructured":"Fraser E.; Denney L.; Antanaviciute A.; Blirando K.; Vuppusetty C.; Zheng Y.; Repapi E.; Iotchkova V.; Taylor S.; Ashley N.; St Noble V.; Benamore R.; Hoyles R.; Clelland C.; Rastrick J.M.D.; Hardman C.S.; Alham N.K.; Rigby R.E.; Simmons A.; Rehwinkel J.; Ho L.P.; Multi-modal characterization of monocytes in idiopathic pulmonary fibrosis reveals a primed type I interferon immune phenotype. Front Immunol  2021,12,623430","journal-title":"Front Immunol"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"735915","DOI":"10.3389\/fphys.2021.735915","volume":"12","author":"Akinbote A.","year":"2021","unstructured":"Akinbote A.; Beltran-Sastre V.; Cherubini M.; Visone R.; Hajal C.; Cobanoglu D.; Haase K.; Classical and non-classical fibrosis phenotypes are revealed by lung and cardiac like microvascular tissues on-chip. Front Physiol  2021,12,735915","journal-title":"Front Physiol"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1001\/archopht.1993.01090030068041","volume":"111","author":"Guyer D.R.","year":"1993","unstructured":"Guyer D.R.; Tiedeman J.; Yannuzzi L.A.; Slakter J.S.; Parke D.; Kelley J.; Tang R.A.; Marmor M.; Abrams G.; Miller J.W.; Interferon-associated retinopathy. Arch Ophthalmol  1993,111(3),350-356","journal-title":"Arch Ophthalmol"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1136\/bjo.79.2.150","volume":"79","author":"Hayasaka S.","year":"1995","unstructured":"Hayasaka S.; Fujii M.; Yamamoto Y.; Noda S.; Kurome H.; Sasaki M.; Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alfa. Br J Ophthalmol  1995,79(2),150-152","journal-title":"Br J Ophthalmol"},{"key":"ref=159","first-page":"309","volume":"91","author":"Kawano T.","year":"1996","unstructured":"Kawano T.; Shigehira M.; Uto H.; Nakama T.; Kato J.; Hayashi K.; Maruyama T.; Kuribayashi T.; Chuman T.; Futami T.; Tsubouchi H.; Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol  1996,91(2),309-313","journal-title":"Am J Gastroenterol"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1111\/j.1572-0241.1998.00701.x","volume":"93","author":"Sugano S.","year":"1998","unstructured":"Sugano S.; Suzuki T.; Watanabe M.; Ohe K.; Ishii K.; Okajima T.; Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C. Am J Gastroenterol  1998,93(12),2441-2444","journal-title":"Am J Gastroenterol"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S0002-9394(01)00836-4","volume":"131","author":"Hejny C.","year":"2001","unstructured":"Hejny C.; Sternberg P.; Lawson D.H.; Greiner K.; Aaberg T.M.; Retinopathy associated with high-dose interferon alfa-2b therapy. Am J Ophthalmol  2001,131(6),782-787","journal-title":"Am J Ophthalmol"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/ICB.0b013e31814b160d","volume":"3","author":"Martinez de Aragon J.S.","year":"2009","unstructured":"Martinez de Aragon J.S.; Pulido J.S.; Haupert C.L.; Blodi C.F.; Nielsen J.S.; Jampol L.M.; Interferon-\u03b2\u2013associated retinopathy. Retin Cases Brief Rep  2009,3(1),24-26","journal-title":"Retin Cases Brief Rep"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s00415-015-7879-0","volume":"263","author":"Gaetani L.","year":"2016","unstructured":"Gaetani L.; Menduno P.S.; Cometa F.; Di Gregorio M.; Sarchielli P.; Cagini C.; Calabresi P.; Di Filippo M.; Retinopathy during interferon-\u03b2 treatment for multiple sclerosis: case report and review of the literature. J Neurol  2016,263(3),422-427","journal-title":"J Neurol"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1034\/j.1600-0676.2001.021003192.x","volume":"21","author":"Saito H.","year":"2001","unstructured":"Saito H.; Ebinuma H.; Nagata H.; Inagaki Y.; Saito Y.; Wakabayashi K.; Takagi T.; Nakamura M.; Katsura H.; Oguchi Y.; Ishii H.; Interferon-associated retinopathy in a uniform regimen of natural interferon-\u03b1 therapy for chronic hepatitis C. Liver  2001,21(3),192-197","journal-title":"Liver"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1007\/s10384-009-0738-8","volume":"53","author":"Kim E.T.","year":"2009","unstructured":"Kim E.T.; Kim L.H.; Lee J.I.; Chin H.S.; Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin. Jpn J Ophthalmol  2009,53(6),598-602","journal-title":"Jpn J Ophthalmol"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/jvh.12135","volume":"20","author":"Raza A.","year":"2013","unstructured":"Raza A.; Mittal S.; Sood G.K.; Interferon-associated retinopathy during the treatment of chronic hepatitis C: A systematic review. J Viral Hepat  2013,20(9),593-599","journal-title":"J Viral Hepat"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/CMR.0000000000000769","volume":"31","author":"Lan S.","year":"2021","unstructured":"Lan S.; Cui Z.; Yin Q.; Liu Z.; Liang L.; He H.; Liu H.; Guo Z.; Yu Y.; Wu D.; Prospective study of clinical characteristics of melanoma patients with retinopathy caused by a high-dose interferon \u03b1-2b. Melanoma Res  2021,31(6),550-554","journal-title":"Melanoma Res"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.3748\/wjg.v12.i23.3756","volume":"12","author":"Okuse C.","year":"2006","unstructured":"Okuse C.; Yotsuyanagi H.; Nagase Y.; Kobayashi Y.; Yasuda K.; Koike K.; Iino S.; Suzuki M.; Itoh F.; Risk factors for retinopathy associated with interferon \u03b1-2b and ribavirin combination therapy in patients with chronic hepatitis C. World J Gastroenterol  2006,12(23),3756-3759","journal-title":"World J Gastroenterol"}],"container-title":["Current Reviews in Clinical and Experimental Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0127724328322183240922153629","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/234860\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0127724328322183240922153629","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T12:11:57Z","timestamp":1744114317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/234860\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":168,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0127724328322183240922153629","relation":{},"ISSN":["2772-4328"],"issn-type":[{"value":"2772-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-05-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}